MARKET

NVTAQ

NVTAQ

Invitae Corp
EXMKT
0.0008
0.0000
0.00%
Closed 15:24 05/24 EDT
OPEN
0.0008
PREV CLOSE
0.0008
HIGH
0.0008
LOW
0.0008
VOLUME
24.27K
TURNOVER
19
52 WEEK HIGH
2.340
52 WEEK LOW
0.0001
MARKET CAP
229.19K
P/E (TTM)
-0.0001
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NVTAQ last week (0520-0524)?
Weekly Report · 1d ago
Weekly Report: what happened at NVTAQ last week (0513-0517)?
Weekly Report · 05/20 09:27
Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 05/13 11:10
Weekly Report: what happened at NVTAQ last week (0506-0510)?
Weekly Report · 05/13 09:28
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Lag Estimates
NASDAQ · 05/09 21:40
Invitae Receives Court Approval For Sale To Labcorp; Key Milestone Reached In Invitae's Chapter 11 Process
Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases. The United States Bankruptcy Court has approved the previously announced bid by labcorp to acquire assets of Invitae. The transaction is expected to bolster labcorP's genetic specialty testing capabilities.
Benzinga · 05/07 21:10
US Bankruptcy Court approves Invitae sale to Labcorp
US Bankruptcy Court approves Invitae sale to Labcorp for $239M in cash. The deal is expected to close in Q3. The company filed for Chapter 11 bankruptcy protection in February. LabcorP says the deal will expand its genetic specialty testing business.
Seeking Alpha · 05/07 20:30
Weekly Report: what happened at NVTAQ last week (0429-0503)?
Weekly Report · 05/06 09:30
More
About NVTAQ
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.

Webull offers Invitae Corp stock information, including EXMKT: NVTAQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVTAQ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVTAQ stock methods without spending real money on the virtual paper trading platform.